{"entity":{"id":"nct04819100","kind":"trial","name":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","aka":["LIBRETTO-432"],"tldr":"A phase 3 trial of Selpercatinib in non-small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.","summary":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT04819100 by Eli Lilly and Company, with 152 participants enrolled, started 2021-12-20 and due to reach its primary completion in 2026-01-12. Interventions recorded: Selpercatinib and Placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04819100","url":"https://clinicaltrials.gov/study/NCT04819100"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","resectable-nsclc","ret-fusion-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["selpercatinib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04819100-n-engl-j-med-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04819100","phase":"3","setting":"LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC","sponsor":"Eli Lilly and Company","started":"2021-12-20","startedType":"actual","enrolled":152,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04819100/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"paper":[{"id":"paper-nct04819100-n-engl-j-med-2026","kind":"paper","name":"Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-nct04819100-n-engl-j-med-2026/"}]}}